Cargando…

Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system

INTRODUCTION: We have evaluated the use of silica–dopamine reservoirs synthesized by the sol–gel approach with the aim of using them in the treatment of Parkinson’s disease, specifically as a device for the controlled release of dopamine in the striatum. Theoretical calculations illustrate that dopa...

Descripción completa

Detalles Bibliográficos
Autores principales: López, Tessy, Bata-García, José L, Esquivel, Dulce, Ortiz-Islas, Emma, Gonzalez, Richard, Ascencio, Jorge, Quintana, Patricia, Oskam, Gerko, Álvarez-Cervera, Fernando J, Heredia-López, Francisco J, Góngora-Alfaro, José L
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025590/
https://www.ncbi.nlm.nih.gov/pubmed/21289978
http://dx.doi.org/10.2147/IJN.S13223
_version_ 1782196931006562304
author López, Tessy
Bata-García, José L
Esquivel, Dulce
Ortiz-Islas, Emma
Gonzalez, Richard
Ascencio, Jorge
Quintana, Patricia
Oskam, Gerko
Álvarez-Cervera, Fernando J
Heredia-López, Francisco J
Góngora-Alfaro, José L
author_facet López, Tessy
Bata-García, José L
Esquivel, Dulce
Ortiz-Islas, Emma
Gonzalez, Richard
Ascencio, Jorge
Quintana, Patricia
Oskam, Gerko
Álvarez-Cervera, Fernando J
Heredia-López, Francisco J
Góngora-Alfaro, José L
author_sort López, Tessy
collection PubMed
description INTRODUCTION: We have evaluated the use of silica–dopamine reservoirs synthesized by the sol–gel approach with the aim of using them in the treatment of Parkinson’s disease, specifically as a device for the controlled release of dopamine in the striatum. Theoretical calculations illustrate that dopamine is expected to assume a planar structure and exhibit weak interactions with the silica surface. METHODS: Several samples were prepared by varying the wt% of dopamine added during the hydrolysis of tetraethyl orthosilicate. The silica–dopamine reservoirs were characterized by N(2) adsorption, scanning and transmission electron microscopy, and Fourier transform infrared spectroscopy. The in vitro release profiles were determined using ultraviolet visible absorbance spectroscopy. The textural analyses showed a maximum value for the surface area of 620 m(2)/g nanostructured silica materials. The stability of dopamine in the silica network was confirmed by infrared and (13)C-nuclear magnetic resonance spectroscopy. The reservoirs were evaluated by means of apomorphine-induced rotation behavior in hemiparkisonian rats. RESULTS: The in vitro dopamine delivery profiles indicate two regimes of release, a fast and sustained dopamine delivery was observed up to 24 hours, and after this time the rate of delivery became constant. Histologic analysis of formalin-fixed brains performed 24–32 weeks after reservoir implantation revealed that silica–dopamine implants had a reddish-brown color, suggesting the presence of oxidized dopamine, likely caused by the fixation procedure, while implants without dopamine were always translucent. CONCLUSION: The major finding of the study was that intrastriatal silica–dopamine implants reversed the rotational asymmetry induced by apomorphine, a dopamine agonist, in hemiparkinsonian rats. No dyskinesias or other motor abnormalities were observed in animals implanted with silica or silica–dopamine.
format Text
id pubmed-3025590
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30255902011-02-02 Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system López, Tessy Bata-García, José L Esquivel, Dulce Ortiz-Islas, Emma Gonzalez, Richard Ascencio, Jorge Quintana, Patricia Oskam, Gerko Álvarez-Cervera, Fernando J Heredia-López, Francisco J Góngora-Alfaro, José L Int J Nanomedicine Original Research INTRODUCTION: We have evaluated the use of silica–dopamine reservoirs synthesized by the sol–gel approach with the aim of using them in the treatment of Parkinson’s disease, specifically as a device for the controlled release of dopamine in the striatum. Theoretical calculations illustrate that dopamine is expected to assume a planar structure and exhibit weak interactions with the silica surface. METHODS: Several samples were prepared by varying the wt% of dopamine added during the hydrolysis of tetraethyl orthosilicate. The silica–dopamine reservoirs were characterized by N(2) adsorption, scanning and transmission electron microscopy, and Fourier transform infrared spectroscopy. The in vitro release profiles were determined using ultraviolet visible absorbance spectroscopy. The textural analyses showed a maximum value for the surface area of 620 m(2)/g nanostructured silica materials. The stability of dopamine in the silica network was confirmed by infrared and (13)C-nuclear magnetic resonance spectroscopy. The reservoirs were evaluated by means of apomorphine-induced rotation behavior in hemiparkisonian rats. RESULTS: The in vitro dopamine delivery profiles indicate two regimes of release, a fast and sustained dopamine delivery was observed up to 24 hours, and after this time the rate of delivery became constant. Histologic analysis of formalin-fixed brains performed 24–32 weeks after reservoir implantation revealed that silica–dopamine implants had a reddish-brown color, suggesting the presence of oxidized dopamine, likely caused by the fixation procedure, while implants without dopamine were always translucent. CONCLUSION: The major finding of the study was that intrastriatal silica–dopamine implants reversed the rotational asymmetry induced by apomorphine, a dopamine agonist, in hemiparkinsonian rats. No dyskinesias or other motor abnormalities were observed in animals implanted with silica or silica–dopamine. Dove Medical Press 2011 2010-12-16 /pmc/articles/PMC3025590/ /pubmed/21289978 http://dx.doi.org/10.2147/IJN.S13223 Text en © 2011 López et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
López, Tessy
Bata-García, José L
Esquivel, Dulce
Ortiz-Islas, Emma
Gonzalez, Richard
Ascencio, Jorge
Quintana, Patricia
Oskam, Gerko
Álvarez-Cervera, Fernando J
Heredia-López, Francisco J
Góngora-Alfaro, José L
Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
title Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
title_full Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
title_fullStr Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
title_full_unstemmed Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
title_short Treatment of Parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
title_sort treatment of parkinson’s disease: nanostructured sol–gel silica–dopamine reservoirs for controlled drug release in the central nervous system
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025590/
https://www.ncbi.nlm.nih.gov/pubmed/21289978
http://dx.doi.org/10.2147/IJN.S13223
work_keys_str_mv AT lopeztessy treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT batagarciajosel treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT esquiveldulce treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT ortizislasemma treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT gonzalezrichard treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT ascenciojorge treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT quintanapatricia treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT oskamgerko treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT alvarezcerverafernandoj treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT heredialopezfranciscoj treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem
AT gongoraalfarojosel treatmentofparkinsonsdiseasenanostructuredsolgelsilicadopaminereservoirsforcontrolleddrugreleaseinthecentralnervoussystem